Laropiprant
Pelzont, Tredaptive, Trevaclyn (laropiprant) is a small molecule pharmaceutical. Laropiprant was first approved as Trevaclyn on 2008-07-03. It has been approved in Europe to treat dyslipidemias. It is known to target prostaglandin D2 receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nutritional and metabolic diseases | D009750 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
44 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypercholesterolemia | D006937 | HP_0003124 | 2 | 1 | 10 | 2 | 1 | 16 | |
| Dyslipidemias | D050171 | HP_0003119 | 2 | 1 | 3 | 4 | — | 10 | |
| Hyperlipidemias | D006949 | EFO_0003774 | E78.5 | — | — | 3 | 1 | — | 4 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | — | 1 | 1 | — | 3 |
| Coronary artery disease | D003324 | I25.1 | — | — | — | 2 | — | 2 | |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | 1 | 1 | — | 2 |
| Coronary disease | D003327 | — | — | 1 | 1 | — | 2 | ||
| Metabolic syndrome | D024821 | EFO_0000195 | E88.81 | — | — | — | 1 | — | 1 |
| Hyperlipoproteinemias | D006951 | — | — | — | 1 | — | 1 | ||
| Hiv | D006678 | O98.7 | — | — | — | 1 | — | 1 |
Show 2 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hyperlipoproteinemia type v | D006954 | Orphanet_70470 | E78.3 | 1 | — | 3 | — | — | 4 |
| Flushing | D005483 | R23.2 | — | 2 | 1 | — | — | 3 | |
| Peripheral arterial disease | D058729 | EFO_0004265 | — | — | 1 | — | 1 | 2 | |
| Hyperlipoproteinemia type ii | D006938 | EFO_0004911 | E78.00 | 1 | — | 1 | — | — | 2 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Asthma | D001249 | EFO_0000270 | J45 | — | 1 | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | LAROPIPRANT |
| INN | laropiprant |
| Description | Laropiprant is an indolyl carboxylic acid. |
| Classification | Small molecule |
| Drug class | prostaglandin receptor antagonists, non prostinoid structure |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CS(=O)(=O)c1cc(F)cc2c3c(n(Cc4ccc(Cl)cc4)c12)[C@@H](CC(=O)O)CC3 |
Identifiers
| PDB | — |
| CAS-ID | 571170-77-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL426559 |
| ChEBI ID | — |
| PubChem CID | 9867642 |
| DrugBank | DB11629 |
| UNII ID | G7N11T8O78 (ChemIDplus, GSRS) |
Target
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 805 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
121 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more